Recombinant factor VIIa treatment for life‐threatening haemoptysis

:  Diffuse alveolar haemorrhage is a severe clinical disorder that may be life‐threatening. The early diagnosis of diffuse alveolar haemorrhage and prompt intervention is crucial. Recombinant factor VIIa has been used extensively for the treatment of haemophilia A and B patients. More recently, reco...

Full description

Saved in:
Bibliographic Details
Published in:Respirology (Carlton, Vic.) Vic.), 2006-09, Vol.11 (5), p.652-654
Main Authors: YILDIRIM, Huseyin, UCGUN, Irfan, YALCIN, Ahmet Ugur, GULBAŞ, Zafer, ŞAhin, Garip, ACIKALIN, Mustafa Fuat, METINTAS, Muzaffer, AK, Guntulu
Format: Article
Language:English
Subjects:
Adult
Coagulants - therapeutic use
diffuse alveolar haemorrhage
Factor VIIa - therapeutic use
haemoptysis
Hemoptysis - drug therapy
Hemoptysis - pathology
Humans
Male
Pulmonary Alveoli
pulmonary–renal syndrome
recombinant factor VIIa
Recombinant Proteins - therapeutic use
respiratory failure
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary::  Diffuse alveolar haemorrhage is a severe clinical disorder that may be life‐threatening. The early diagnosis of diffuse alveolar haemorrhage and prompt intervention is crucial. Recombinant factor VIIa has been used extensively for the treatment of haemophilia A and B patients. More recently, recombinant factor VIIa has been used successfully for the treatment of bleeding in patients without pre‐existing coagulopathy. We describe the successful use of recombinant factor VIIa in a patient with diffuse alveolar haemorrhage secondary to pulmonary–renal syndrome.
ISSN:1323-7799
1440-1843
DOI:10.1111/j.1440-1843.2006.00906.x